Naproxen), at the end of the 2 weeks of active treatment. Eligible subjects were not current Non-Steroidal trading analysis software Anti-Inflammatory Drug (NSAID) users, had controlled hypertension, and could receive stable doses of up to 2 different classes of antihypertensive drugs. This ABPM pilot study in hypertensive volunteers was designed to compare the 24-hour blood pressure profiles of naproxcinod candlestick charting software 750 mg bid and naproxen 500 mg bid.
Is headquartered in France and is listed on the Euronext Paris Stock Exchange (Compartment B. Naproxcinod is NicOx' lead investigational product and the first compound in the new Cyclooxygenase-Inhibiting metastock Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents. "This new analysis of the blood pressure data from the 104 study follows the excellent top-line results we announced last week for the 111 study. Resources are focused on the development of naproxcinod, candlestick charting software a proprietary NCE and the first compound in the Cyclooxygenase-Inhibiting free stock charting software mac Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is in phase 3 clinical tradestation software price studies for the treatment of the signs and symptoms of osteoarthritis, with final phase 3 results anticipated in 2008. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance trading analysis tool or achievements of NicOx S.A. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ candlestick analysis forex materially from those anticipated in the forward-looking statements.
The metastock review results of the trading analysis tool third phase 3 trial for naproxcinod (the 303 study) are expected before the end of the year and the filing of a New Drug Application (NDA) for naproxcinod with the U.S. New analysis of the 104 ABPM study presented at the American Heart Association. NicOx is applying its proprietary nitric oxide-donating technology scientific graphing software review to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic nasdaq trading analysis software disease. Conway Hanks Director of Investor Relations and Corporate Communication Tel 33 (0)4 97 24 53 42 - Media in the United States - FD Paxton Stanislaro - Tel 1 212 850 5657 - Sarajane Gomez-Dib - Tel 1 212 850 5761 - Media in Europe - Citigate Dewe Rogerson Jaimie Dible - Tel 44 (0)207 282 2949 - Krissie Enegren - Tel 44 (0)207 282 1050 - NicOx S.A., This information is provided by tradestation comparison with amibroker metastock HUGIN.
Both these ABPM trials suggest that naproxcinod's 24 hour blood pressure profile is improved compared to naproxen's and we are eager to receive the results of the ongoing 112 ABPM study in the coming months." The 104 trial was an 8-week, double-blind, randomized, cross-over study, in which 131 hypertensive volunteers between 50 and 75 years of age were enrolled to receive either naproxcinod 750 mg bid for 2 weeks, follo by naproxen 500 mg bid for 2 weeks, or these compounds in the reverse order. NicOx is developing naproxcinod in late phase 3 clinical studies, which are designed to demonstrate that moving average crossover it is safe, well tolerated and effective for treating the signs and symptoms of osteoarthritis, in addition to having no detrimental effect on blood pressure, in contrast to traditional NSAIDs and COX-2 inhibitors. Interestingly, for the daytime measurements (the 8 hours following the morning dose), the mean 8-hour SBP sho a difference of 4.4 mmHg (standard error 0.98 mmHg) in favor of naproxcinod as compared to naproxen (p 0.0001) tradestation reviews after 2 weeks of treatment. Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, widespread eye diseases and Chronic Obstructive Pulmonary Disease (COPD). Food and Drug Administration (FDA) is projected for mid 2009. NCOX.PA) a product-driven tradestation software reviews biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. To differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference filed with the AMF, which is available on the AMF website ) or on NicOx S.A.'s website ).
This new post hoc analysis was accepted by the American Heart Association scientific panel and compared the mean 24-hour systolic blood pressure (SBP) as measured by ABPM in the two groups (i.e. This contains certain forward-looking statements. "It was very interesting and rewarding to share these promising results with the medical community at the American Heart Association Scientific Sessions, which is one of the leading cardiology congresses worldwide," commented Demetri Djian MD, Cardiologist and Vice-President Translational Medicine at NicOx. The mean 24-hour SBP sho a difference of 2.4 mmHg (standard error 0.87 mmHg) in favor of naproxcinod as compared to naproxen (p 0.007) after 2 weeks of treatment. COX) today announced that a new analysis of the data from the 104 Ambulatory Blood Pressure Monitoring (ABPM) study for naproxcinod was presented at the American Heart Association Scientific Sessions 2008, in New Orleans, USA. Subjects received a 2-week placebo broddie out at the beginning of the study and between the active treatment periods.
.